ADAR1 Capital Management, LLC purchased $1.6M of NXTC (indirect holdings)
ADAR1 Capital Management, LLC purchased 329,153 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.93 ($4.80–$5.00, $1.62M total) across 9 trades over 2026-07-30 to 2026-07-31.
How this was made
The 30-second read
Why it matters
ADAR1 Capital Management, a 10% owner, reported an open-market purchase of 329,153 shares across 9 trades at a weighted average price of $4.9342, totaling $1,624,120.50, with holdings after the transaction of 722,419 shares.
Market read
Traders may treat the buy as a modest sentiment input, but it does not replace fundamental catalysts.
What to watch
The filing is indirect and does not disclose the underlying rationale, timing constraints, or whether other insiders are buying or selling concurrently.
Background
The article is an SEC Form 4 insider transaction disclosure for NextCure, Inc. (NXTC).
Ticker impact
NextCure disclosed an open-market purchase by a 10% owner, ADAR1 Capital Management, totaling about $1.62M at ~$4.93 per share.
Likely limited near-term impact; any effect is more sentiment-driven than valuation-changing.
Form 4 insider buys can support sentiment, but the article provides no new operating, regulatory, or clinical-trial information, and the transaction is spread across multiple small trades.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide regulatory or clinical read-through.
None indicated.
None indicated.
Counterpoint
A 10b5-1 plan is not indicated, but the buy could still be routine rebalancing or tax/portfolio management rather than a strong forward-looking signal.
Key entities
- issuerNextCure, Inc.
Subject of the Form 4 insider transaction disclosure (NXTC).
- insiderADAR1 Capital Management, LLC
Reporter and 10% owner that purchased NXTC shares indirectly.
